U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. Science and Research Special Topics
  4. Clinical Trials and Human Subject Protection
  5. Center BIMO Program Contacts
  1. Science and Research Special Topics

Center BIMO Program Contacts

Center BIMO Program Contacts


Biological Products

Bioresearch Monitoring Branch
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research (CBER)
Telephone: 240-402-8010
Facsimile: 301-595-1245
Email: ocod@fda.hhs.gov

Contact the Bioresearch Monitoring Branch for questions about:
  • The legal status of a test article
  • Human subject protection regulations related to biologics
  • CBER assigned IRB inspections
  • CBER assigned clinical investigator inspections
  • Reports made pursuant to 21 CFR 56.108(b) and 56.113 involving a biologic product including:
    • unanticipated problems involving risks to subjects
    • serious or continuing noncompliance by an investigator with FDA regulations or with the IRB's determinations
    • suspension or termination of IRB approval of a protocol

Drug Products

Office of Scientific Investigations (OSI)
Office of Compliance
Center for Drug Evaluation and Research (CDER)
Telephone: 301-796-3150
Facsimile: 301-847-8748
Email: CDER-OSI-GCPReferrals@fda.hhs.gov

Contact the Office of Scientific Investigations for questions about:
  • Human subject protection regulations pertaining to drugs (21 CFR Parts 50, 56, 312, 320, 361)
  • CDER-assigned IRB inspections
  • Reports made pursuant to 21 CFR 56.108(b) and 56.113 involving a drug product including:
    • unanticipated problems involving risks to subjects [21 CFR 56.108(b)(1)]
    • serious or continuing noncompliance by an investigator with FDA regulations or with the IRB's determinations [21 CFR 56.108 (b)(2)]
    • suspension or termination of IRB approval of a protocol [21 CFR 56.108(b)(3)]
  • Reporting complaints related to human subject protection/good clinical practice in FDA-regulated drug trials

Enforcement Information

Division of Compliance Policy
Office of Enforcement
Office of Regulatory Affairs
Telephone: 240-632-6800
Fax: 240-632-6810

Contact the Division of Compliance Policy for questions about:
  • FDA’s Bioresearch Monitoring Program, Compliance Programs, and the Good Laboratory Practice (GLP) Program for nonclinical laboratories
  • Bioresearch Monitoring Program enforcement issues

Food or other products regulated by the Center for Food Safety and Applied Nutrition

Bioresearch Monitoring Program
Office of Center Director
Center for Food Safety and Applied Nutrition (CFSAN)
Phone: 240-402-1757
Fax: 301-436-2668

Contact the Bioresearch Monitoring Program for questions about:
  • Human subject protection related to studies involving foods or other CFSAN-regulated products
  • CFSAN-regulated products include:
    • food additives
    • color additives
    • infant formula
    • dietary supplements
  • Human subject protection related to petitions for nutrient content claims and health claims
  • Reporting complaints related to the conduct of clinical trials of CFSAN-regulated products

Medical Devices

Division of Bioresearch Monitoring
Office of Compliance
Center for Device and Radiological Health (CDRH)
Phone: 301-796-5490
Fax: 301-847-8136
Website: Bioresearch Monitoring

Contact the Division of Bioresearch Monitoring for questions about:

  • Human subject protection regulations pertaining to devices [21 CFR Parts 50, 56, and 812]
  • Informed consent, standard operating procedures, records and reports in clinical trials for medical devices
  • Serious or continuing noncompliance by an investigator with FDA regulations or with the IRB's determinations involving a medical device [21 CFR 56.108(b)(2)]
  • Reporting complaints related to human subject protection/good clinical practice in FDA-regulated medical device trials

New Animal Drugs

Premarket Compliance and Administrative Action Team
Center for Veterinary Medicine (CVM)
Phone: 240-276-9200
Fax: 240-276-9241

Contact the Premarket Compliance and Administrative Actions Team for questions about:
  • Good clinical practice regulations related to new animal drugs for investigational use (21 CFR Part 511)
  • Reporting complaints related to the conduct of studies with new animal drugs for investigational use